A new study published by Cleveland Clinic researchers investigating the genetic underpinnings of weight loss response has identified a gene, neurobeachin (NBEA), as a predictor of how individuals respond to GLP-1RAs, the class of medications behind popular treatments like liraglutide and semaglutide.<\/p>\n
\u00a0<\/p>\n
While GLP-1RAs have shown promise in helping individuals lose weight, their effectiveness varies widely. This study, which analyzed large-scale real-world data from the NIH All of Us cohort and the UK Biobank, discovered that individuals with certain genetic variations of NBEA \u2014a gene encoding a protein kinase A anchor protein\u2014 are significantly more likely to experience substantial weight loss\u2014or, conversely, non-responsiveness\u2014when prescribed GLP-1RAs.<\/p>\n
\u00a0<\/p>\n
Key findings include:<\/p>\n
Individuals with a “responsive” NBEA genetic score were up to 82% more likely to achieve significant weight loss with liraglutide and semaglutide.Those with a “non-responsive” NBEA score were up to 50% more likely to not lose weight on liraglutide.Validation across two independent cohorts strengthens the reliability of these results.<\/p>\n
\u00a0<\/p>\n
This research paves the way for personalized obesity treatment strategies, allowing healthcare providers to use genetic insights to identify patients most likely to benefit from GLP-1RA medications.<\/p>\n
\u00a0<\/p>\n